Related Experiment Video
Updated: Aug 10, 2026

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
Published on: November 16, 2016
Fluoroquinolone benchmarking in relation to pharmacokinetic and pharmacodynamic parameters
Joseph A Paladino1, Wendy A Callen
1CPL Associates LLC, 3980 Sheridan Drive, Amherst, NY 14226, USA. paladino@cplassociates.com
Abstract:
The expanding class of fluoroquinolone antibiotics comprises numerous agents that differ in pharmacokinetic (PK) characteristics as well as pharmacodynamic (PD) activity. Although generally considered as potent compounds as a class, their individual in vitro activities, as measured by minimum inhibitory concentrations (MIC) demonstrate considerable variability. Objective pharmacological measures such as Cmax/MIC and AUC24/MIC, also known as area under the inhibitory curve (AUIC), have been shown to predict bacteriological eradication, clinical efficacy, emergence of resistant substrains and economic results. These PK/PD measures describe in vivo potency and can provide scientific guidance to clinicians when deciding which agent to use at the bedside of individual patients, and to healthcare administrators when deciding the formulary status for individual agents.
Related Concept Videos
Measurement of Bioavailability: Pharmacokinetic Methods
Measurement of Bioavailability: Pharmacodynamic Methods
Dosage Regimens: Partial Pharmacokinetic Parameters
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
Pharmacodynamic Models: Overview
Pharmacodynamic Models: Linear Concentration–Effect Model

